XOMA (NASDAQ:XOMA) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS

XOMA (NASDAQ:XOMA – Get Rating) announced its quarterly earnings results on Wednesday. The biotechnology company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.04, Fidelity Earnings reports. XOMA had a return on equity of 4.93% and a net margin of 14.57%.

XOMA stock opened at $19.12 on Friday. The company has a market cap of $217.89 million, a P/E ratio of 127.48 and a beta of 1.09. XOMA has a twelve month low of $17.86 and a twelve month high of $39.02. The business has a fifty day moving average of $24.67 and a 200-day moving average of $23.08.

In other XOMA news, CEO James R. Neal sold 1,111 shares of the business’s stock in a transaction dated Wednesday, March 23rd. The stock was sold at an average price of $30.02, for a total value of $33,352.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Thomas M. Burns sold 2,339 shares of the business’s stock in a transaction dated Tuesday, March 22nd. The shares were sold at an average price of $30.02, for a total value of $70,216.78. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 53,450 shares of company stock valued at $1,553,569. 10.90% of the stock is owned by insiders.

Large investors have recently bought and sold shares of the business. State Street Corp grew its stake in XOMA by 2.2% in the fourth quarter. State Street Corp now owns 129,876 shares of the biotechnology company’s stock valued at $2,708,000 after acquiring an additional 2,752 shares during the period. Millennium Management LLC boosted its position in shares of XOMA by 187.4% during the fourth quarter. Millennium Management LLC now owns 25,982 shares of the biotechnology company’s stock worth $542,000 after buying an additional 16,943 shares during the period. Morgan Stanley boosted its position in shares of XOMA by 276.0% during the third quarter. Morgan Stanley now owns 9,889 shares of the biotechnology company’s stock worth $245,000 after buying an additional 7,259 shares during the period. Barclays PLC boosted its position in shares of XOMA by 196.8% during the fourth quarter. Barclays PLC now owns 7,310 shares of the biotechnology company’s stock worth $152,000 after buying an additional 4,847 shares during the period. Finally, Bank of America Corp DE boosted its position in shares of XOMA by 80.3% during the fourth quarter. Bank of America Corp DE now owns 6,761 shares of the biotechnology company’s stock worth $141,000 after buying an additional 3,012 shares during the period. 56.11% of the stock is owned by hedge funds and other institutional investors.

Several analysts recently commented on XOMA shares. TheStreet raised XOMA from a “c-” rating to a “b-” rating in a research note on Friday, April 1st. Zacks Investment Research downgraded XOMA from a “hold” rating to a “strong sell” rating in a research report on Saturday, January 8th. StockNews.com downgraded XOMA from a “buy” rating to a “hold” rating in a research report on Friday, April 22nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $69.00 price objective on shares of XOMA in a research report on Monday, May 2nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, XOMA presently has a consensus rating of “Hold” and a consensus price target of $49.00.

About XOMA (Get Rating)

XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.

Read More